Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ TDIF2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA560731
Description
Immunogen sequence: PSQESHTEAI SDAETSSSDI SFSGIATRRT RSMQRKLKAQ TEKKDSKIVP GNEKQIVGTP VNSEDSDTRQ TSHLQARSLS EINKPNFYNN DFDDDFSHR Highest antigen sequence identity to the following orthologs: Mouse - 50%, Rat - 55%.
This gene is thought to be involved in chromatin remodeling and gene transcription. The encoded nuclear protein binds to and enhances the transcriptional activity of the estrogen receptor alpha, and also interacts with terminal deoxynucleotidyltransferase. The expression profile of this gene is a potential biomarker for chronic obstructive pulmonary disease.
Specifications
TDIF2 | |
Polyclonal | |
Unconjugated | |
DNTTIP2 | |
4930588M11Rik; AA408582; acidic 82 kDa protein mRNA; AU014960; deoxynucleotidyltransferase terminal interacting protein 2; deoxynucleotidyltransferase terminal-interacting protein 2; deoxynucleotidyltransferase, terminal, interacting protein 2; DNTTIP2; ERBP; estrogen receptor binding protein; Estrogen receptor-binding protein; FCF2; HSU15552; LPTS-interacting protein 2; LPTS-RP2; TDIF2; tdT-interacting factor 2; Terminal deoxynucleotidyltransferase-interacting factor 2 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
30836 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.22 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q5QJE6 | |
DNTTIP2 | |
Recombinant protein corresponding to Human TDIF2. Recombinant protein control fragment (Product #RP-94005). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction